MedTrace Logo

Preferences for Certainty Versus Access When Evaluating New Cancer Drugs. A Discrete Choice Experiment.

NCT05936632 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 998

Last updated 2024-06-11

No results posted yet for this study

Summary

To provide timely access to new treatments, some eligible drugs can be approved despite uncertainty surrounding the level of clinical benefit they offer patients.

It is not currently known if (and under which circumstances) people would prefer to wait to access some new drugs in exchange for greater certainty surrounding their clinical benefit.

This study aims to elicit the preferences of people in the US with experience of cancer for wait times and clinical uncertainty of new drugs.

To elicit this information, in a survey format, respondents will be presented with a hypothetical scenario and asked to state their preferences for new treatments, each with different attributes.

Conditions

Interventions

OTHER

Discrete Choice Experiment (DCE)

DCE survey experiment

Sponsors & Collaborators

  • London School of Economics and Political Science

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2023-07-20
Completion
2023-07-20

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05936632 on ClinicalTrials.gov